Merck, known as MSD outside the United States and Canada, announced today that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series with Senior Management to discuss Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation on June 22, 2021, at 9:00 a.m. EDT.

About Merck

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.